Corona Remedies Limited

BSE: 544644 NSE: CORONA
Corona Remedies Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24231GJ2004PLC044656 Incorporated 27 August 2004 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: CORONA · BSE: 544644 Public Limited Company pharma
Data last updated
Market Cap
₹13,278 Cr
CORONA · NSE
Share Price
₹2,271.60
+4.63% today
Revenue
₹1,403 Cr
FY 2025-26 · +17.3% YoY
EBITDA
₹274 Cr
Margin 19.6%
Net Profit
₹200 Cr
FY 2025-26 · +33.3% YoY
P/E (TTM)
62.0x
P/B 17.6x
ROE
27.4%
ROCE 28.9%
Debt / Equity
0.19
Interest cover 3.0x

About Corona Remedies Limited

Data last updated:

Corona Remedies Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 August 2004 and has been in existence for over 22 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ2004PLC044656. Its GSTIN is 24AACCC5173F2ZX (Gujarat). The company holds 27 GST registrations, of which 20 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 544644 and NSE: CORONA.

The company has an authorised share capital of ₹61.17 Cr and a paid-up capital of ₹61.16 Cr. It is led by directors including Niravkumar Kirtikumar Mehta (Managing Director) and Ankur Kirtikumar Mehta (Managing Director).

Its last annual general meeting (AGM) was held on 09 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mondeal Business Park, Ahmedabad, Gujarat.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,403.18 Cr, a growth of 17.3% compared to the previous year. For the same year it recorded a net profit of ₹199.86 Cr (net margin 14.2%) and EBITDA of ₹274.34 Cr (EBITDA margin 19.6%). The net worth stands at ₹746.86 Cr (up 23.2% YoY). Total assets are valued at ₹977.78 Cr (up 33.7% YoY).

The company has about 4,625 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Corona Remedies. As per MCA filings, the company has open charges of ₹70.25 Cr and satisfied charges of ₹112.58 Cr on record. Court records list 45 cases involving the company, including 32 filed by the company and 13 filed against it; 11 cases are pending. The company has 32 deals on record (21 secondary share transfers, 7 funding rounds, 3 market trades), with disclosed funding of ₹101.3 Cr; the latest was in June 2026. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Sentiss Pharma Private Limited with revenue of ₹1,262.74 Cr. The company has 18 MSME Form 1 returns on record between 2019 and 2023, listing 736 overdue payments to 107 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website coronaremedies.com.

Company details

CIN L24231GJ2004PLC044656
Registration Number 044656
Incorporation Date 27 August 2004
ROC Ahmedabad
Listing Status Listed - Listed on NSE (CORONA); Listed on BSE (544644)
Company Status Active
Date of Last AGM 09 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Corona Remedies has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ2004PLC044656, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231GJ2004PLC044656Current
U24231GJ2004PTC044656Previous
U24231GJ2004PLC044656Previous
Key People
Niravkumar Kirtikumar Mehta Managing Director Ankur Kirtikumar Mehta Managing Director Viral Sitwala Whole-Time Director

Contact details

Corona Remedies Limited's registered office is in Daskroi, Gujarat. Its website is coronaremedies.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    coronaremedies.com
  • Social Media
  • Registered Address
    Corona House C – Mondeal Business Park, Near Gurudwara S. G. Highway, Ahmedabad, Gujarat, India – 380059
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Corona Remedies Limited, buy the company report.

Comprehensive company report
Corona Remedies Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Corona Remedies operates one associated brand: Corona Remedies. Each brand links to its own profile.

BrandDescriptionWebsite
Corona Remedies
Manufacturer of pharmaceutical products focused on women's health, cardio-diabetology, pain management, and urologycoronaremedies.com

Business activity

The main business activity of Corona Remedies is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Corona Remedies Limited, buy the company report.

Financials of Corona Remedies Limited

FY 2025-26 filings available

Corona Remedies Limited reported revenue of ₹1,403.18 Cr (up 17.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,403 Cr
+17.3% YoY
EBITDA
₹274 Cr
+14.3% YoY
Profit After Tax
₹200 Cr
+33.3% YoY
Net Worth
₹747 Cr
+23.2% YoY
Total Assets
₹978 Cr
+33.7% YoY
Total Debt
₹165 Cr
+91.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue1,4031,1961,014884
Revenue growth+17.3%+17.9%+14.8%-
EBITDA274240155128
EBITDA margin+19.6%+20.1%+15.3%+14.5%
Profit before tax240199118111
Net profit20015091.1984.81
Net profit margin+14.2%+12.5%+9.0%+9.6%
EPS (₹)30.2724.4314.8013.89
Balance sheet
Total assets978731671462
Net worth747606480409
Total debt16586.2415927.96
Cash & bank44.1269.2769.9076.70
Net working capital133148135152
Cash flow
Cash from operations229190157103
Cash from investing(256)(83.86)(267)(50.28)
Cash from financing25.28(107)98.55(44.75)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422353342361347294298314
Revenue growth (YoY)+21.9%+20.2%+15.0%+15.1%+19.0%---
Other income3.164.392.262.442.021.630.942.46
EBITDA93.1362.0264.0678.4769.5854.2269.4266.81
EBITDA margin+22.0%+17.6%+18.7%+21.7%+20.1%+18.5%+23.3%+21.3%
Depreciation13.2410.299.459.208.9210.049.699.05
Interest2.691.381.661.931.992.202.392.87
Profit before tax80.3654.7455.2169.7860.6943.6158.2857.35
Tax20.259.4113.9417.4614.4912.0613.3314.38
Net profit60.1145.3341.2752.3246.2031.5544.9542.97
EPS (₹)9.837.416.758.557.555.167.357.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,4031,1961,014884617576601
Revenue growth+17.3%+17.9%+14.8%+43.2%+7.2%-4.2%-
EBITDA27424015512817.8310592.19
EBITDA margin+19.6%+20.1%+15.3%+14.5%+2.9%+18.3%+15.3%
Profit before tax240198118111(0.78)92.4177.44
Net profit20015091.2084.60(0.57)69.9359.03
Net profit margin+14.2%+12.5%+9.0%+9.6%-0.1%+12.1%+9.8%
EPS (₹)30.2224.3714.8013.85(0.08)150.71126.69
Balance sheet
Total assets977731671462381415336
Net worth746606480408321338268
Total debt16586.2415927.9633.7449.8846.52
Cash & bank44.1269.2769.9076.7010143.3239.55
Net working capital133148135152146179172
Cash flow
Cash from operations22919015710397.7079.1643.01
Cash from investing(256)(83.86)(267)(50.28)(65.81)(102)(50.25)
Cash from financing25.28(107)98.54(44.75)(29.86)0.0930.16
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422353342361347294298314
Revenue growth (YoY)+21.9%+20.2%+15.0%+15.1%+19.0%---
Other income3.154.112.242.272.021.420.762.46
Total expenses329291278283277239228247
EBITDA93.1362.0264.0678.4769.7854.2269.4266.82
EBITDA margin+22.0%+17.6%+18.7%+21.7%+20.1%+18.5%+23.3%+21.3%
Depreciation13.2410.299.459.208.9210.049.699.05
Interest2.691.381.661.931.992.202.392.87
Profit before tax80.3554.4655.1969.6160.8943.4058.1057.36
Tax20.259.4113.9417.4614.4912.0613.3314.38

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 03 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422353342361347294298314
Revenue growth (YoY)+21.9%+20.2%+15.0%+15.1%+19.0%---
Other income3.164.392.262.442.021.630.942.46
EBITDA93.1362.0264.0678.4769.5854.2269.4266.81
EBITDA margin+22.0%+17.6%+18.7%+21.7%+20.1%+18.5%+23.3%+21.3%
Depreciation13.2410.299.459.208.9210.049.699.05
Interest2.691.381.661.931.992.202.392.87
Profit before tax80.3654.7455.2169.7860.6943.6158.2857.35
Tax20.259.4113.9417.4614.4912.0613.3314.38
Net profit60.1145.3341.2752.3246.2031.5544.9542.97
EPS (₹)9.837.416.758.557.555.167.357.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue1,4031,1961,014884
Revenue growth+17.3%+17.9%+14.8%-
Other income10.926.316.467.28
Total expenses1,129956860756
Employee cost403346295255
EBITDA274240155128
EBITDA margin+19.6%+20.1%+15.3%+14.5%
Depreciation37.8737.1628.2820.10
Interest6.9710.6014.444.27
Profit before tax240199118111
Tax55.3049.1027.9825.96
Net profit20015091.1984.81
Net profit margin+14.2%+12.5%+9.0%+9.6%
EPS (₹)30.2724.4314.8013.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital61.1661.1661.1661.16
Reserves & surplus686545419347
Shareholders' funds (net worth)747606480409
Minority interest0.000.000.000.00
Secured loans14362.701342.33
Unsecured loans21.9923.5424.8125.63
Total debt16586.2415927.96
Total liabilities978731671462
Assets
Gross block724503483256
Net block554370384185
Capital work in progress14318612164.71
Investments26.2925.9625.5531.50
Inventories12512998.35105
Sundry debtors14611899.9386.99
Cash & bank balances44.1269.2769.9076.70
Loans & advances33.6421.8321.7316.43
Total current assets348339290286
Total current liabilities215190155133
Net working capital133148135152
Total assets978731671462
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash3.223.1614.496.82
Net cash from operating activities229190157103
Net cash from investing activities(256)(83.86)(267)(50.28)
Net cash from financing activities25.28(107)98.55(44.75)
Net change in cash(1.39)0.06(11.34)7.67
Closing cash44.1269.2769.9076.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+17.3%+17.9%+14.8%-
EBITDA growth+14.3%+55.1%+20.9%-
PBT growth+21.1%+67.6%+6.8%+9997.0%
Net income growth+33.3%+64.5%+7.5%-
Revenue CAGR (3Y)+16.7%---
EBITDA CAGR (3Y)+28.9%---
Profitability & leverage
Net income margin+13.2%+12.5%+8.9%+9.6%
Return on capital employed+29.0%+29.8%+23.5%+24.9%
Return on net worth+27.4%+27.5%+20.4%+20.8%
Debt / equity0.190.230.210.07
Long-term debt / equity0.040.120.130.06
Interest cover2.955.2311.423.96
Efficiency & per share
Fixed asset turnover2.292.432.743.45
Inventory turnover11.0310.509.968.39
Debtors turnover10.6410.9710.8510.16
EPS (₹)30.2724.4314.8013.89
Dividend per share (₹)10.007.313.702.77
Book value per share (₹)122.1299.1478.5566.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue422353342361347294298314
Revenue growth (YoY)+21.9%+20.2%+15.0%+15.1%+19.0%---
Other income3.154.112.242.272.021.420.762.46
Total expenses329291278283277239228247
EBITDA93.1362.0264.0678.4769.7854.2269.4266.82
EBITDA margin+22.0%+17.6%+18.7%+21.7%+20.1%+18.5%+23.3%+21.3%
Depreciation13.2410.299.459.208.9210.049.699.05
Interest2.691.381.661.931.992.202.392.87
Profit before tax80.3554.4655.1969.6160.8943.4058.1057.36
Tax20.259.4113.9417.4614.4912.0613.3314.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,4031,1961,014884617576601
Revenue growth+17.3%+17.9%+14.8%+43.2%+7.2%-4.2%-
Other income10.655.936.467.056.604.943.48
Total expenses1,129956860756600471509
Employee cost403346295255227176164
EBITDA27424015512817.8310592.19
EBITDA margin+19.6%+20.1%+15.3%+14.5%+2.9%+18.3%+15.3%
Depreciation37.8737.1628.2820.1020.4815.8915.97
Interest6.9710.6014.444.274.732.012.26
Profit before tax240198118111(0.78)92.4177.44
Tax55.3049.1027.9825.95(0.39)22.4818.65
Net profit20015091.2084.60(0.57)69.9359.03
Net profit margin+14.2%+12.5%+9.0%+9.6%-0.1%+12.1%+9.8%
EPS (₹)30.2224.3714.8013.85(0.08)150.71126.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital61.1661.1661.1661.5551.054.644.64
Reserves & surplus685545419347270333263
Shareholders' funds (net worth)746606480408321338268
Secured loans14362.701342.3333.7431.8228.02
Unsecured loans21.9923.5424.8125.630.0018.0618.50
Total debt16586.2415927.9633.7449.8846.52
Total liabilities977731671462381415336
Assets
Gross block72450348325621419696.38
Net block55437038418516216480.63
Capital work in progress14318612164.7114.230.0041.92
Investments25.4025.3425.3131.2714.0636.897.32
Inventories12512998.3510573.9530.6022.98
Sundry debtors14611899.9386.9974.35207173
Cash & bank balances44.1269.2769.9076.7010143.3239.55
Loans & advances33.6421.8321.7316.4327.3514.818.31
Total current assets348339290286277296244
Total current liabilities21519015513313111771.90
Net working capital133148135152146179172
Total assets977731671462381415336
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.223.1614.496.824.7927.654.72
Net cash from operating activities22919015710397.7079.1643.01
Net cash from investing activities(256)(83.86)(267)(50.28)(65.81)(102)(50.25)
Net cash from financing activities25.28(107)98.54(44.75)(29.86)0.0930.16
Net change in cash(1.39)0.06(11.34)7.672.04(22.86)22.93
Closing cash44.1269.2769.9076.7010143.3239.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.3%+17.9%+14.8%+43.2%+7.2%-4.2%-
EBITDA growth+14.3%+55.1%+20.9%+617.8%-83.1%+14.3%-
PBT growth+21.2%+67.3%+7.1%+9998.0%-+19.3%-77.6%
Net income growth+33.4%+64.0%+7.8%--100.8%+18.5%-
Revenue CAGR (3Y)+16.7%+24.7%+20.8%+13.7%+6.6%--
EBITDA CAGR (3Y)+28.9%+137.9%+13.7%+11.6%-63.2%--
Profitability & leverage
Net income margin+13.2%+12.5%+8.9%+9.6%-0.1%+12.1%+9.8%
Return on capital employed+29.0%+29.8%+23.5%+27.3%+1.0%+25.1%+28.2%
Return on net worth+27.4%+27.5%+20.4%+23.2%-0.2%+23.1%+24.7%
Debt / equity0.190.230.210.080.130.160.12
Long-term debt / equity0.040.120.130.060.070.080.04
Interest cover2.955.2311.423.96-178.492.252.97
Efficiency & per share
Fixed asset turnover2.292.432.743.763.013.945.99
Inventory turnover11.0310.509.969.8611.8121.5124.12
Debtors turnover10.6410.9710.8510.964.393.033.92
EPS (₹)30.2224.3714.8013.85(0.08)150.71126.69
Dividend per share (₹)10.007.313.702.770.000.000.00
Book value per share (₹)121.9799.0478.5166.7062.86727.91577.56

To see the full year-wise statements and ratios of Corona Remedies Limited, buy the company report.

Board of directors of Corona Remedies Limited

Corona Remedies has 8 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Viral SitwalaWhole-Time Director01 Jan 201016 Years 10 MonthsCurrent
Niravkumar Kirtikumar Mehta
Also directs: NKM Nextgen LLP
Managing Director30 May 200719 Years 5 MonthsCurrent
Ankur Kirtikumar Mehta
Also directs: Klnext Enterprise LLP
Managing Director27 Aug 200422 Years 2 MonthsCurrent
Kirtikumar Laxmidas MehtaDirector27 Aug 200422 Years 2 MonthsCurrent
Ameetkumar Hiranyakumar Desai
Also directs: Anubhuti Advisors LLP, Ambuja Cements Limited, Ganesh Housing Limited and 5 more
Director22 Nov 20223 Years 11 MonthsCurrent
Shirish Gundopant Belapure
Also directs: Bellapure Onco Phytoceuticals LLP, Jubilant Pharmova Limited, Innova Captab Limited and 3 more
Director04 Jan 20251 Years 9 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Corona Remedies Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Corona Remedies Limitedthis company₹1,403.18 Cr (FY 2026)₹199.86 Cr14.2%17.3%4,625Ahmedabad, Gujarat, India
Sentiss Pharma Private Limited₹1,262.74 Cr (FY 2025)43.0%New Delhi, Delhi, India
Innova Captab Limited₹1,255.72 Cr (FY 2025)15.0%Thane, Maharashtra, India
Cipla Health Limited₹1,228.87 Cr (FY 2025)17.0%Mumbai, Maharashtra, India
Neon Laboratories Limited₹1,222.81 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Hetero Healthcare Limited₹1,189.8 Cr (FY 2025)16.0%Hyderabad, Telangana, India
BDR Pharmaceuticals International Private Limited₹1,137.31 Cr (FY 2025)2.0%Mumbai, Maharashtra, India
Tirupati Medicare Limited₹1,119.15 Cr (FY 2025)6.0%New Delhi, Delhi, India
Zuventus Healthcare Limited₹1,117.95 Cr (FY 2025)4.0%Pune, Maharashtra, India
Medley Pharmaceuticals Limited₹1,114.92 Cr (FY 2025)8.0%Mumbai, Maharashtra, India

To see the full peer comparison of Corona Remedies Limited, buy the company report.

Auditor

Corona Remedies Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & Sells LLPFY 2025117366W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 69.00%, foreign institutional investors hold 3.60%, domestic institutional investors hold 12.90% and retail and other public shareholders hold 14.50%.

Promoters: 69.00%DII (Domestic Institutional): 12.90%FII (Foreign Institutional): 3.60%Retail & Others: 14.50%
Sep 2026
QUARTER
69.00% Promoters
12.90% DII (Domestic Institutional)
3.60% FII (Foreign Institutional)
14.50% Retail & Others
Promoter holding - history
Now 69.00% · Sep 2026High 69.00% · Dec 2025Low 69.00% · Dec 2025
68%68.5%69%69.5%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 69.00%Mar 2026: 69.00%Jun 2026: 69.00%Sep 2026: 69.00%69.00%69.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters69.00%69.00%69.00%69.00%
Public31.00%31.00%31.00%31.00%

Charges & borrowings

Open charges
₹70.25 Cr
Satisfied charges
₹112.58 Cr
Breakdown by lending institutions
Others₹50.25 Cr
Citi Bank N.A.₹20.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
22 Jul 2026101356630Others₹25.16 LakhOpen
22 Dec 2023100835664Others₹50 CrOpen
07 Jul 2023100749708Citi Bank N.A.₹20 CrOpen
28 Aug 2019100286564Others₹32.75 LakhSatisfied
22 Aug 2019100285475Others₹60.61 LakhSatisfied

To see the full charge records of Corona Remedies Limited, buy the company report.

Total charge records: 15 View all charges

Deals & funding

Corona Remedies Limited has 32 deals on record (21 secondary share transfers, 7 funding rounds, 3 market trades), with disclosed funding of ₹101.3 Cr; the latest was in June 2026.

Total deals
32
Secondary share transfers
21
Funding rounds
7
Market trades
3
IPO
1
Disclosed funding
₹101.3 Cr

Deals on record (5 of 32)

WhenDealAmountParties
Jun 2026Market trade₹776.91 CrBuyer: Hdfc Mutual Fund, Aditya Birla Sun Life Mutual Fund, Aberdeen Asian Smaller Companies Investment Trust Plc
Seller: Sepia Investments Limited, Anchor Partners
Jun 2026Market trade₹748.91 CrBuyer: Hdfc Mutual Fund, Aditya Birla Sun Life Mutual Fund, Aberdeen Asian Smaller Companies Investment Trust Plc
Seller: Sepia Investments Limited
Dec 2025Market trade₹340.95 CrBuyer: Invesco Mutual Fund, Marwadi Chandarana Intermediaries Brokers Private Limited , Junomoneta Finsol Private Limited
Seller: Marwadi Chandarana Intermediaries Brokers Private Limited , Junomoneta Finsol Private Limited
Dec 2025IPO₹655.37 CrInvestors: SBI Healthcare Opportunities Fund, Sbi Life Insurance Company Limited , DSP Healthcare Fund
Seller: Anchor Partners, Sage Investment Trust, Sepia Investments Limited
Oct 2024Secondary share transferUndisclosedBuyer: 3 individuals
Seller: 3 individuals

To see the full deal history of Corona Remedies Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Corona Remedies Limited was last rated by Care on 20 Dec 2021.

Rating agencyRated onRating
Care20 Dec 2021

To see the full credit ratings and regulatory alerts of Corona Remedies Limited, buy the company report.

MSME payment delays

Corona Remedies Limited has 18 MSME Form 1 returns on record between 2019 and 2023, listing 736 overdue payments to 107 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 107)

SupplierAmount dueDue sinceReported on
Meteoric Biopharmaceuticals Private Limited
Prachin Chemical
Suramya Ventures LLP
Aarohi Print Pack
Saffron Enterprises Private Limited

To see the full MSME payment records of Corona Remedies Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Corona Remedies has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Associated companies

Employees & EPFO

Corona Remedies Limited has a workforce of 4,625 employees on its EPFO records as of Dec 24, 2025, across 1 active EPFO establishment.

Employee count
4,625
Active EPFO establishments
1
Employee growth
3.19%

GST

Corona Remedies has 27 GST registrations: 20 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
27
Active
20
Cancelled / inactive
7
GSTINStateStatusRegistered on
24AACCC5173F2ZXGujaratActive10 Oct 2017
24AACCC5173F3ZWGujaratActive14 Sep 2020
02AACCC5173F1Z4Himachal PradeshActive01 Jul 2017
08AACCC5173F2ZRRajasthanActive27 Sep 2021

To see the full GST registrations and return filing status of Corona Remedies Limited, buy the company report.

Recent activity

Corona Remedies Limited has 22 board changes on record since 2004: 10 appointments and 12 cessations. The latest: Kshitij Pankaj Sheth ceased to be Nominee Director on 23 Apr 2025.

Charges
A charge with Citi Bank N.A. of Rs. 20.00 Cr registered on 07 Jul 2023 with Charge ID 100749708 was modified on 06 Oct 2026.
Charges
A charge with Others amounted to Rs. 0.25 Cr with Charge ID 101356630 was registered on 22 Jul 2026.
AGM
Corona Remedies Limited last Annual general meeting of members was held on 09 Jul 2026 as per latest MCA records.
Filing
Corona Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Ceased
Kshitij Pankaj Sheth ceased to be Nominee Director.
Appointed
Chetna Prabhatkumar Dharajiya was appointed as Company Secretary.
Appointed
Bhaskar Vemban Iyer was appointed as Director.
Appointed
Shirish Gundopant Belapure was appointed as Director.
Ceased
Bhavin Nareshbhai Bhagat ceased to be CEO.
Appointed
Bhavin Nareshbhai Bhagat was appointed as CFO.
Appointed
Monica Hemal Kanuga was appointed as Director.
Ceased
Monica Hemal Kanuga ceased to be Additional Director.

47 earlier events are in the company report.

News

CORONA: Q2 REVENUE 4.4B RUPEES VS 3.6B (YOY)
30 Oct 2026 · Exchange Update
CORONA: Q2 SL NET PROFIT 602M RUPEES VS 522M (YOY)
30 Oct 2026 · Exchange Update
CORONA: Q2 EBITDA 961M RUPEES VS 790M (YOY); Q2 EBITDA MARGIN 21.80% VS 21.88% (YOY)
30 Oct 2026 · Exchange Update
Corona Remedies: Co. Receives GMP Compliance Certification From Anvisa, Brazil For OSD And Hormone Manufacturing Facilities; Located In Bhayla, Ahmedabad.
22 Oct 2026 · Exchange Update
Corona Remedies: Company Gets ANVISA GMP Certification for Bhayla Manufacturing Plant in Brazil.
22 Oct 2026 · Exchange Update

Frequently asked questions

Corona Remedies is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 August 2004 (22+ years old) and is registered under CIN L24231GJ2004PLC044656. Listed on BSE: 544644 and NSE: CORONA.

Corona Remedies reported revenue of ₹1,403.18 Cr for FY 2025-26 (up 17.3% YoY) based on consolidated financials.

Corona Remedies has 8 current directors:

The latest financial statements of Corona Remedies on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 09 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Corona Remedies is 24AACCC5173F2ZX, registered in Gujarat. The company has 27 GST registrations in all, of which 20 are active and 7 are cancelled or inactive. Other active GSTINs include 24AACCC5173F3ZW (Gujarat), 02AACCC5173F1Z4 (Himachal Pradesh), 08AACCC5173F2ZR (Rajasthan).

The CIN (Corporate Identification Number) of Corona Remedies is L24231GJ2004PLC044656. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Corona Remedies is a listed company as per MCA records. Its shares are listed on both BSE (code: 544644) and NSE (symbol: CORONA).

Corona Remedies has 45 court cases on record: 32 filed by the company and 13 filed against it. 11 are pending. Most are in the district courts.

Corona Remedies was incorporated on 27 August 2004, making it 22+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Corona Remedies has 32 deals on record (21 secondary share transfers, 7 funding rounds, 3 market trades), with disclosed funding of ₹101.3 Cr; the latest was in June 2026.

The peers of Corona Remedies by revenue are Sentiss Pharma Private Limited, Innova Captab Limited, Cipla Health Limited, Neon Laboratories Limited, Hetero Healthcare Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Kshitij Pankaj Sheth ceased to be Nominee Director on 23 Apr 2025. Chetna Prabhatkumar Dharajiya was appointed as Company Secretary on 18 Apr 2025. Bhaskar Vemban Iyer was appointed as Director on 04 Jan 2025. Corona Remedies has 22 board changes on record in total.